Based on this finding, and on the aforementioned studies in other cancer types, we can postulate that YM155, in addition to promoting tumor cell apoptosis by inhibiting survivin, downregulates EGFR expression in breast cancer cells that highly express both BIRC5 and EGFR. Here, EGFR is linked to breast cancer.